Next Issue
Volume 15, April
Previous Issue
Volume 14, December
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Curr. Oncol., Volume 15, Issue 1 (January 2008) – 12 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
28 KiB  
Article
San Antonio Breast Cancer Symposium 2007—Adjuvant Endocrine Therapy Update: ATAC 100 Highlights
by Anil A. Joy
Curr. Oncol. 2008, 15(1), 68-69; https://doi.org/10.3747/co.2008.203 - 01 Jan 2008
Viewed by 453
Abstract
The two main classes of adjuvant hormonal therapy used in the treatment of postmenopausal women with hormone receptor–positive breast cancer are selective estrogen receptor modulators (for example, tamoxifen) and the aromatase inhibitors (AIs—for example, anastrozole, letrozole, exemestane). [...] Full article
156 KiB  
Article
Trastuzumab in the Adjuvant Setting: Concurrent or Sequential? It Takes Two to Tango!
by Sunil Verma
Curr. Oncol. 2008, 15(1), 66-67; https://doi.org/10.3747/co.2008.204 - 01 Jan 2008
Cited by 5 | Viewed by 487
Abstract
Two months ago, on routine physical examination by family physician, a 58-year-old woman was diagnosed with a breast lump. [...] Full article
27 KiB  
Article
“Crack Lung and Heart” Presenting after Chemotherapy in a 65-Year-Old Man with Non-Hodgkin Lymphoma
by G. G. Alvarez and R. H. C. van der Jagt
Curr. Oncol. 2008, 15(1), 63-65; https://doi.org/10.3747/co.2008.202 - 01 Jan 2008
Cited by 4 | Viewed by 549
Abstract
Crack cocaine can cause a variety of pulmonary and cardiac complications. Pulmonary findings in a 65- year-old man with non-Hodgkin lymphoma who presented with shortness of breath not resolving with antibiotics are presented here. The usual manifestation of “crack lung” in an unusual [...] Read more.
Crack cocaine can cause a variety of pulmonary and cardiac complications. Pulmonary findings in a 65- year-old man with non-Hodgkin lymphoma who presented with shortness of breath not resolving with antibiotics are presented here. The usual manifestation of “crack lung” in an unusual clinical circumstance underlines the importance of a clinical history in such cases. The finding of “crack lung” preceded the diagnosis of probable “crack heart.” No other similar published case reports could be identified in the literature. Full article
1011 KiB  
Article
Radiation Recall Dermatitis: Case Report and Review of the Literature
by A. E. Hird, J. Wilson, S. Symons, E. Sinclair, M. Davis and E. Chow
Curr. Oncol. 2008, 15(1), 53-62; https://doi.org/10.3747/co.2008.201 - 01 Jan 2008
Cited by 59 | Viewed by 1120
Abstract
“Radiation recall”—also called “radiation recall dermatitis”—has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been [...] Read more.
“Radiation recall”—also called “radiation recall dermatitis”—has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented. Here, we report a rare occurrence of the radiation recall phenomenon in a breast cancer patient after palliative radiotherapy for bone, brain, and orbital metastases. Full article
198 KiB  
Article
The Ontario Cancer Research Ethics Board: A Central REB That Works
by M. R. Chaddah
Curr. Oncol. 2008, 15(1), 49-52; https://doi.org/10.3747/co.2008.196 - 01 Jan 2008
Cited by 14 | Viewed by 617
Abstract
The Ontario Cancer Research Ethics Board (ocreb) has made its mark within Ontario as a successful, centralized, oncology-specific research ethics board. As such, ocreb has proven invaluable to principal investigators, sponsors, and study participants given its ability to reduce duplication during the submission [...] Read more.
The Ontario Cancer Research Ethics Board (ocreb) has made its mark within Ontario as a successful, centralized, oncology-specific research ethics board. As such, ocreb has proven invaluable to principal investigators, sponsors, and study participants given its ability to reduce duplication during the submission process, to provide the highest quality of review, to shorten study start-up time, and to implement more efficient methods of reporting serious adverse events. Full article
166 KiB  
Article
Chinese Medicine and Biomodulation in Cancer Patients—Part One
by S. M. Sagar and R. K. Wong
Curr. Oncol. 2008, 15(1), 42-48; https://doi.org/10.3747/co.2008.197 - 01 Jan 2008
Cited by 62 | Viewed by 705
Abstract
Traditional Chinese Medicine (tcm) may be integrated with conventional Western medicine to enhance the care of patients with cancer. Although tcm is normally implemented as a whole system, recent reductionist research suggests mechanisms for the effects of acupuncture, herbs, and nutrition [...] Read more.
Traditional Chinese Medicine (tcm) may be integrated with conventional Western medicine to enhance the care of patients with cancer. Although tcm is normally implemented as a whole system, recent reductionist research suggests mechanisms for the effects of acupuncture, herbs, and nutrition within the scientific model of biomedicine. The health model of Chinese medicine accommodates physical and pharmacologic interventions within the framework of a body–mind network. A Cartesian split does not occur within this model, but to allow for scientific exploration within the restrictions of positivism, reductionism, and controls for confounding factors, the components must necessarily be separated. Still, whole-systems research is important to evaluate effectiveness when applying the full model in clinical practice. Scientific analysis provides a mechanistic understanding of the processes that will improve the design of clinical studies and enhance safety. Enough preliminary evidence is available to encourage quality clinical trials to evaluate the efficacy of integrating tcm into Western cancer care. Full article
213 KiB  
Article
Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma
by N. Levesque, K. Mitchinson, D. Lawrie, L. Fedorak, D. MacDonald, C. Normand and J.F. Pouliot
Curr. Oncol. 2008, 15(1), 36-41; https://doi.org/10.3747/co.2008.200 - 01 Jan 2008
Cited by 11 | Viewed by 608
Abstract
The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 [...] Read more.
The goal of the 1-year observational, multicentre, open-label study reported here was to identify factors influencing adherence to high-dose interferon alfa-2b adjuvant therapy in patients at high risk of recurrence following surgical excision of malignant melanoma. The study was carried out in 23 tertiary-care centres across Canada. Full article
192 KiB  
Article
Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
by J. R. Mackey, M. Clemons, M.A. Côté, D. Delgado, S. Dent, A. Paterson, L. Provencher, M.B. Sawyer and S. Verma
Curr. Oncol. 2008, 15(1), 24-35; https://doi.org/10.3747/co.2008.199 - 01 Jan 2008
Cited by 138 | Viewed by 1244
Abstract
Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (her2) protein. In the pivotal metastatic breast cancer trials, cardiac dysfunction was observed in women treated with trastuzumab and chemotherapy. [...] Read more.
Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (her2) protein. In the pivotal metastatic breast cancer trials, cardiac dysfunction was observed in women treated with trastuzumab and chemotherapy. The incidence and severity of cardiac dysfunction was greatest among patients who received trastuzumab in combination with anthracycline-based therapy. Those findings influenced the design of subsequent trastuzumab trials to include prospective evaluations of cardiac effects and protocols for cardiac monitoring and management. The risk of cardiotoxicity has also driven efforts to develop non-anthracycline-based regimens for women with her2-positive breast cancers. With the increasing use of trastuzumab, particularly in the curative adjuvant setting, the need for a rational approach to the treatment and cardiac management of the relevant patient population is clear. The mandate of the Canadian Trastuzumab Working Group was to formulate recommendations, based on available data, for the assessment and management of cardiac complications during adjuvant trastuzumab therapy. The panel formulated recommendations in four areas: (1) Risk factors for cardiotoxicity; (2) Effects of various regimens (3) Monitoring (4) Management The recommendations published here are expected to evolve as more data become available and experience with trastuzumab in the adjuvant setting grows. Full article
440 KiB  
Article
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
by C.T. Kouroukis, S. Chia, S. Verma, D. Robson, C. Desbiens, C. Cripps and J. Mikhael
Curr. Oncol. 2008, 15(1), 9-23; https://doi.org/10.3747/co.2008.198 - 01 Jan 2008
Cited by 23 | Viewed by 770
Abstract
Hematologic toxicities of cancer chemotherapy are common and often limit the ability to provide treatment in a timely and dose-intensive manner. These limitations may be of utmost importance in the adjuvant and curative intent settings. Hematologic toxicities may result in febrile neutropenia, infections, [...] Read more.
Hematologic toxicities of cancer chemotherapy are common and often limit the ability to provide treatment in a timely and dose-intensive manner. These limitations may be of utmost importance in the adjuvant and curative intent settings. Hematologic toxicities may result in febrile neutropenia, infections, fatigue, and bleeding, all of which may lead to additional complications and prolonged hospitalization. The older cancer patient and patients with significant comorbidities may be at highest risk of neutropenic complications. Colony-stimulating factors (csfs) such as filgrastim and pegfilgrastim can effectively attenuate most of the neutropenic consequences of chemotherapy, improve the ability to continue chemotherapy on the planned schedule, and minimize the risk of febrile neutropenia and infectious morbidity and mortality. The present consensus statement reviews the use of csfs in the management of neutropenia in patients with cancer and sets out specific recommendations based on published international guidelines tailored to the specifics of the Canadian practice landscape. We review existing international guidelines, the indications for primary and secondary prophylaxis, the importance of maintaining dose intensity, and the use of csfs in leukemia, stem-cell transplantation, and radiotherapy. Specific disease-related recommendations are provided related to breast cancer, non-Hodgkin lymphoma, lung cancer, and gastrointestinal cancer. Finally, csf dosing and schedules, duration of therapy, and associated acute and potential chronic toxicities are examined. Full article
43 KiB  
Article
Protein Tyrosine Phosphatases: New Markers and Targets in Oncology?
by S. Hardy and M. L. Tremblay
Curr. Oncol. 2008, 15(1), 5-8; https://doi.org/10.3747/co.2008.195 - 01 Jan 2008
Cited by 6 | Viewed by 465
Abstract
The discovery nearly 30 years ago that v-src (the form of the Src kinase encoded by Rous sarcoma virus) employs tyrosine kinase activity for transforming cells [...]
Full article
127 KiB  
Article
Moses Judah Folkman 1933–2008
by P. Gold
Curr. Oncol. 2008, 15(1), 4; https://doi.org/10.3747/co.2008.194 - 01 Jan 2008
Cited by 1 | Viewed by 420
Abstract
On January 14, a bright light in the field of cancer research was extinguished with the sudden death of Dr. Judah Folkman. Folkman first introduced the concept [...]
Full article
128 KiB  
Editorial
In this issue of Current Oncology
by M. McLean
Curr. Oncol. 2008, 15(1), 3; https://doi.org/10.3390/curroncol15010001 - 01 Jan 2008
Viewed by 319
Abstract
The year 2008 will see the continued expansion of Current Oncology, Canada’s only multidisciplinary journal devoted to cancer. [...] Full article
Previous Issue
Next Issue
Back to TopTop